Cancer and Leukemia Group B Studies in Relapsed AML
In the past 20 years, substantial progress has been made in the treatment of acute myeloid leukemia (AML), previously a uniformly fatal diseae. Initial treatment usually consists of a combination of cytosine arabinoside (Ara-C) and daunorubicin, and complete remission (CR) is achieved in approximately 65 % of patients with somewhat higher response rates in younger patients. Once CR is achieved, further chemotherapy is necessary to pro?duce long term disease free survival. How?ever, the majority of patients will relapse; despite the use of these two active drugs as postremission therapy in schedules that have included a 30-fold increase in the dose of Ara-C, there has been, at best, only a modest improvement in survival. Thus, despite 15 year of use of the combination of daunorubicin and Ara-C, the fraction of patients cured with chemotherapy remains in the range 20%–25 % [1–5]. Substantial improvement in long-term disease-free survival has been elusive.
KeywordsAcute Myeloid Leukemia Complete Remission Complete Remission Rate Postremission Therapy Bone Marrow Aplasia
Unable to display preview. Download preview PDF.
- 1.Cassileth PA, Begg CB, Silber R, Spiers A, Burkart PT, Scharfman W, Knospe WH, Bennett JM, Mazza JJ, Oken MM, Keller AM, O’Connell MJ (1987) Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. Cancer Treat Rep 71: 137–140PubMedGoogle Scholar
- 2.DutcherJP,Wiernik PH, Markus S,Weinberg V, Schiffer CA, Harwood KV (1989) Intensive maintenance therapy improves survival in adult acute nonlymphocytic leukemia: an eight-year follow-up. Leukemia 2: 413–419Google Scholar
- 3.Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ (1986) Principal results of the Medical Research Council’s 8th acute myeloid leukemia trial. Lancet II: 1236–1241Google Scholar
- 4.Schiffer CA, Mayer RJ for the CALGB (1990) Cancer and Leukemia Group B (CALGB) Studies in acute myeloid leukemia. In: Gale RP (ed) Acute myelogenous leukemia: progress and controversies. Wiley/Liss, New York, pp 313Google Scholar
- 6.Bachur NR, Collins JM, Kelley JA,Van Echo DA, Kaplan RS, Whitacre M (1982) Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics. Clin Pharmacol Ther 31: 650–655Google Scholar
- 15.Lee EJ, Paciucci A, Amrein P, Schulman P, Davis R, Schiffer CA (1990) A randomized phase II trial of three regimens in the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults: a CALGB study. Blood 76 [Suppl]: 294aGoogle Scholar
- 16.Brown RA, Herzig RH,Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Lowder JN, Harden EA, Hande KR, Herzig GP (1990) High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76: 473–479Google Scholar